A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
Clinical trial NCT07520760 · RECRUITING
Trial details
- NCT number
- NCT07520760
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2030-04-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.